Brain organoids promise medical breakthroughs but demand ethical governance to prevent exploitation and unintended consequences
Original framing: “Brain organoids are a transformative technology — but they need regulation” — Nature
The development of brain organoids is rooted in a history of exploitative medical research, from the Tuskegee syphilis experiments to the unethical use of Henrietta Lacks' cells. Colonial-era practices of tissue collection in Africa and Asia laid the groundwork for today's biotech industry, where Global South populations remain sources of cheap biological material. The patenting of human genes and tissues, exemplified by the 1980 Diamond v. Chakrabarty case, established the legal framework for the commercialization of life. These precedents reveal a pattern of prioritizing scientific progress over human dignity, which continues in the organoid field.
The brain organoid debate is not merely a scientific or regulatory challenge but a collision of historical injustices, cultural worldviews, and power asymmetries in global health.
The current framing, dominated by Western scientific institutions, obscures the colonial legacies of tissue extraction and the communal perspectives that challenge the commodification of life. Indigenous and marginalized voices reveal that the ethical stakes extend beyond individual consent to fundamental questions about personhood, relational accountability, and the sacredness of biological material. Meanwhile, the scientific community grapples with unresolved questions about consciousness, while corporate interests push for a regulatory framework that prioritizes profit over equity. A systemic solution requires dismantling extractive practices through decolonized governance, centering marginalized voices in oversight, and developing pluralistic ethical standards that honor both scientific progress and cultural diversity. Without this, the promise of organoids will remain a tool of inequality rather than liberation.